eujo_Kolari.jpg Host Laboratory


Position in LIMMS

EUJO-LIMMS Researcher (VTT)

Main Research Topic in LIMMS

Integrated microfluidic system for gastrointestinal tract analogue for prodrug screening with on-line monitoring

Keywords Microfluidic analogue, Prodrug, Cancer

Institute of Industrial Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan 
Phone:+81 (0)3 5452 6036 / Fax:+81 (0)3 5452 6088


VTT Technical Research Centre of Finland 
Tietotie 3, P.O. Box 1000, FI-02044 VTT, Espoo, Finland
Tel. +358 40 8251703  /  Fax +358 20 722 7012

E-mail kai.kolari[at]vtt.fi
Download icon_pdf.gifAbstract2013_KKolari.pdf


Short resume :
2012-now Actual position
2008 - 2012 Here
2004-2008 Here
2001-2004 Here

↑Page top

Research Projects in Limms

1- Topic 1
Context :
The classic ways to induce selection pressure for cell cultures is injecting different doses of active agent into microtiter plate, flow-through cell or chemostat. Using microfluidics the necessary features of 3D restrictions, surfaces and controlled flow of many liquids in channels are achieved for conditions approaching in-vivo. The compartmentalized microfluidic analogue of a mammalian body will also lead to a decreased number of animal tests which clearly benefits the huge medical industry pursuing the ways to reduce this type of thus far necessary element. Based on IIS’s [1] and also others’ [2-3] experience mammalian cells can be placed to an interactive microfluidic system.
Objectives & Methods :
As PDMS microfluidic device is capable of mimicking a functional body, this study pursues for two-flow on-line monitoring and characterization of prodrugs never tested in a microfluidic analogue. In this work a microfluidic device was built to mimic human body circulation for studying action of a lung cancer drug on the viability of lung cancer cells (A549). In this device the prodrug was aimed to be introduced to the system via thin membrane (intestinal cells), metabolized to actual drug in liver (area with liver cells) and transferred then to the lungs (area with lung cancer cells) via heart (micropump).
Initial tests showed that HEPG2 could not be used in the experiments, as it was less resistant to Tegafur drug than A549 target cancer cells. Therefore primary HEP was chosen for main experiments.  
Results :
Within the 48-hour time frame it was difficult to see the effect of Tegafur and Uracil on the target A549 cells in the microfluidic device. The staining method used in the work revealed only few dead cells and many improvements for experimental conditions was suggested.
                                                                                     Fig. 1 The approach used in this work consisting of human body (left) that is mimicked by the analogue (right).
References and publications :
[1] Kimura H. et al., Lab on a chip 8, pp. 741-746, 2008. 
[2] Mahler G. J. et al., Biotechnology and Bioengineering 104, pp. 193-205, 2009. 
[3] Jong HS. Et al., Lab on a chip 10, pp. 446-455, 2010.

↑Page top

Main publication List (papers, conferences and patent)







2010 and prior



↑Page top